The International
LungCancerSummit
Where Leaders in Thoracic Oncology UniteAgainst Lung Cancer||To Share Knowledge||To Exchange||To Debate||To Advance Care||To Fight Cancer||To Drive Progress||To Provide Insights
Your invitation · 2 min
A word from our faculty
Choose your calendar
Google Calendar (Online)
Outlook Calendar (Offline)
Outlook On Microsoft Office 365 (Online)
Outlook On The Web (Online)
Apple Offline Calendar / iCalThe programme · 13 Nov 2026
CME-certified
Expert-Driven Education & Insights
A day built around what changes practice
Debate · which is the better choice in 1L ES-SCLC?
Panel · open questions & patient cases
All speakers & attendeesPartners & supporters
Backed, independently
The ILCS is supported by 13 industry partners, with no influence on the content.
For sponsoring opportunities, please contact us at sponsoring@lungsummit.org
Accreditation
5 CME credits
Accredited by UEMS–EACCME & the Swiss Society of Medical Oncology
Programme to be announced
Programme to be announced
Led by global experts
The people in the room
A global roster of oncologists, surgeons and pathologists — chaired from Lausanne, drawn from across the field.
Solange Peters
Chair, Switzerland
Alfredo Addeo
Chair, Switzerland
Umberto Malapelle
Italy
Hidehito Horinouchi
Japan
Telma Sequeira
Portugal
Christine Lovly
USA
David Planchard
France
Sandip Patel
USA
Alessio Cortellini
Italy
Lauren Byers
USA
Giannis Mountzios
Greece
Anne-Marie Dingemans
Netherlands
Where we meet · Lausanne
On site & online
Hosted at CHUV in Lausanne and live-streamed worldwide — join in person, or from your own clinic.
ILCS · In frames
ILCS 2025, in Lausanne
A day on the ground — faculty, debate and the room between sessions.
Beyond the summit
Year-round education
The summit doesn’t stop in November. Watch every ILCS session on demand — plus webinars, expert debates and interviews, released all year and CME-certified.
Find your area
Browse by topic
Live & upcoming
Upcoming events
Live symposia, webinar series and new interviews between summits — released and CME-certified all year.
Coming soon · 13:00 CET · Salamanca Auditorium, Hall 10 · ESMO Congress 2026, Madrid
SCLC Symposium at ESMO 2026: From IO-Standards to the TCE Era
Speakers
Agenda & discussion topics
The Role of Immune Checkpoint Blockade in SCLC: Achievements & Limitations
Redefining the Standards: The Era of DLL3 T-Cell Engagers
Practical Management of DLL3 T-Cell Engagers
The Evolving Algorithm: Sequencing Innovative StrategiesChoose your calendar
Coming soon · 09:45 CET · Lausanne + Live online
The International Lung Cancer Summit 2026
Chairs
Speakers
UmbertoMalapelle
HidehitoHorinouchi
TelmaSequeira
ChristineLovly
DavidPlanchard
SandipPatel
AlessioCortellini
LaurenByersGiannisMountzios
Anne-MarieDingemansChoose your calendar
The library
Watch on demand
Featured sessions
Advances in EGFR+ NSCLC: An Interview with Prof. Oliver Gautschi
Prof. Oliver Gautschi discusses recent advances in the treatment of EGFR-mutant non-small cell lung cancer in this on-demand expert interview.
Approaches in Metastatic PD-L1 Negative NSCLC: An Interview with Prof. Alessandra Curioni-Fontecedro
Prof. Alessandra Curioni-Fontecedro discusses treatment approaches in metastatic PD-L1 negative non-small cell lung cancer in this on-demand expert interview.
Expert Insights
2025 Approvals & Highlights
1 h 49 min
Reshaping Approaches in SCLC with the Latest Advances in LS- and ES-Disease
34 min
Latest Options for Non-Oncogene Addicted Advanced NSCLC in Frontline and Beyond
32 min
The Reading Room
Radiation plus durvalumab without chemotherapy cleared its survival target in frail LA-NSCLC patients
EGFR amplification at baseline marks shorter time on first-line osimertinib, in exon 19 deletions but not L858R
EVOKE-01 biomarker analysis: Trop-2 staining did not pick out who does better on sacituzumab govitecan than docetaxel
ORCHARD final data: osimertinib plus gefitinib gives modest benefit in EGFR C797X, and the authors advise against further study
Zidesamtinib approved in the US for previously treated ROS1-positive non-small cell lung cancer
Sac-TMT plus pembrolizumab improves PFS in PD-L1-negative NSCLC
Patient Cases
Let us discuss your patient in our expert roundtables
Submit an anonymised case or a question — the faculty take it up live at our webinars and at ILCS. The questions you carry into clinic, answered by the people writing the guidelines.
Stay in the room
Join our network in thoracic oncology
One considered email when something lands — new sessions, the next roundtable, the next live event.